AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20708275 — intervention group
Group type: COMPARATOR
Intervention: Hormonal measures (Estradiol, Prolactin, Cortisol) and IL-6
Number of subjects: 56
Study 18725656 — intervention group
Group type: EXPERIMENTAL
Intervention: Walk in the park (20 minutes)
Number of subjects: 17
Study 18725656 — intervention group
Group type: COMPARATOR
Intervention: Downtown walk (20 minutes)
Number of subjects: 17
Study 18725656 — intervention group
Group type: COMPARATOR
Intervention: Neighborhood walk (20 minutes)
Number of subjects: 17
Study 17177665 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5% phenylephrine (group 1)
Number of subjects: 44
Study 17177665 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4% benoxinate followed by 2.5% phenylephrine (group 2)
Number of subjects: 44
Study 17177665 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 44
Study 14963679 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational integrated rehabilitation program (2.5-3 hours twice a week for 15 weeks according to BAR guidelines) with annual check-ups.
Number of subjects: 40000
Study 14963679 — intervention group
Group type: COMPARATOR
Intervention: Evidence-based treatment in cooperation with general practitioner (GP).
Number of subjects: 40000
Study 14963679 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 40000
Study 12131291 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-aminolevulinic acid fluorescence endoscopy
Number of subjects: 129
Study 12131291 — intervention group
Group type: COMPARATOR
Intervention: White light endoscopy
Number of subjects: 129
Study 9602583 — intervention group
Group type: EXPERIMENTAL
Intervention: HBOC‐201 0.4 g kg‐1
Number of subjects: 12
Study 9602583 — intervention group
Group type: COMPARATOR
Intervention: HES 3 ml kg‐1
Number of subjects: 12
Study 8031049 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin 350 mg orally every 8 hours for one week
Number of subjects: 10
Study 8031049 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 2746448 — intervention group
Group type: EXPERIMENTAL
Intervention: active antimicrobial mouthrinse
Number of subjects: 99
Study 2746448 — intervention group
Group type: COMPARATOR
Intervention: control mouthrinse
Number of subjects: 99
Study 909027 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of povidone iodine on umbilical cord and normal intact skin
Number of subjects: 0
Study 909027 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of povidone iodine on denuded skin
Number of subjects: 0
Study 909027 — intervention group
Group type: COMPARATOR
Intervention: Topical application of povidone iodine
Number of subjects: 0
Study 30978622 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure Therapy (PE)
Number of subjects: 87
Study 30978622 — intervention group
Group type: COMPARATOR
Intervention: Relaxation Training (RT)
Number of subjects: 87
Study 30978622 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure Therapy (PE) and Relaxation Training (RT)
Number of subjects: 87
Study 29122072 — intervention group
Group type: EXPERIMENTAL
Intervention: CHX containing GIC
Number of subjects: 90
Study 29122072 — intervention group
Group type: EXPERIMENTAL
Intervention: CHX cavity disinfection
Number of subjects: 90
Study 29122072 — intervention group
Group type: COMPARATOR
Intervention: Conventional GIC
Number of subjects: 90
Study 1447501 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium fluoride (50 mg/day)
Number of subjects: 22
Study 1447501 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 22844045 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flexion rotating-platform posterior-stabilised design (RP-F)
Number of subjects: 77
Study 22844045 — intervention group
Group type: COMPARATOR
Intervention: Standard fixed-bearing posterior cruciate ligament-preserving design (FB-S)
Number of subjects: 77
Study 20060078 — intervention group
Group type: EXPERIMENTAL
Intervention: teriparatide 20 mug/day by subcutaneous injection
Number of subjects: 197
Study 20060078 — intervention group
Group type: COMPARATOR
Intervention: alendronate 10 mg/day orally
Number of subjects: 197
Study 18689571 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 g resistant maltodextrin
Number of subjects: 38
Study 18689571 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 g maltodextrin plus 7.5 g resistant maltodextrin
Number of subjects: 38
Study 18689571 — intervention group
Group type: COMPARATOR
Intervention: 15 g maltodextrin
Number of subjects: 38
Study 16739679 — intervention group
Group type: EXPERIMENTAL
Intervention: Random practice schedule
Number of subjects: 0
Study 16739679 — intervention group
Group type: COMPARATOR
Intervention: Blocked practice schedule
Number of subjects: 0
Study 12689733 — intervention group
Group type: EXPERIMENTAL
Intervention: Radioactive iodine tagged with lipiodol
Number of subjects: 0
Study 12689733 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 10674014 — intervention group
Group type: EXPERIMENTAL
Intervention: MLT (20 mg/day orally every day) plus chemotherapy
Number of subjects: 250
Study 10674014 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 250
Study 8932544 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG-liposomal doxorubicin
Number of subjects: 18
Study 8932544 — intervention group
Group type: COMPARATOR
Intervention: Standard doxorubicin
Number of subjects: 18
Study 2006741 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% ropivacaine
Number of subjects: 30
Study 2006741 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75% ropivacaine
Number of subjects: 30
Study 2006741 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% ropivacaine
Number of subjects: 30
Study 2006741 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg ropivacaine
Number of subjects: 30
Study 2006741 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg ropivacaine
Number of subjects: 30
Study 2006741 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromage scale
Number of subjects: 30
Study 2006741 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative method for motor blockade
Number of subjects: 30
Study 6137468 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol (beta-adrenergic antagonist)
Number of subjects: 19
Study 6137468 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 31674060 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg of prolonged-release melatonin (Circadin), ingested orally once-daily before bedtime
Number of subjects: 30
Study 31674060 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo, ingested orally once-daily before bedtime
Number of subjects: 30
Study 30956109 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-administered Cognitive Behavioral Therapy (CBT) for 7 weeks
Number of subjects: 137
Study 30956109 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control receiving the intervention after 8 weeks
Number of subjects: 137
Study 30479202 — intervention group
Group type: COMPARATOR
Intervention: Standard MTM (SMTM)
Number of subjects: 342
Study 30479202 — intervention group
Group type: COMPARATOR
Intervention: MTM incorporating clinical decision support tool (CMTM)
Number of subjects: 342
Study 30479202 — intervention group
Group type: COMPARATOR
Intervention: CMTM enhanced by pharmacogenetic test results (PGxMTM)
Number of subjects: 342
Study 30479202 — intervention group
Group type: EXPERIMENTAL
Intervention: PGxMTM
Number of subjects: 342
Study 30479202 — intervention group
Group type: EXPERIMENTAL
Intervention: All DTPs
Number of subjects: 342
Study 30479202 — intervention group
Group type: EXPERIMENTAL
Intervention: DTPs from PGxMTM arm
Number of subjects: 342
Study 26938989 — intervention group
Group type: EXPERIMENTAL
Intervention: Adductor Canal Block (ACB)
Number of subjects: 100
Study 26938989 — intervention group
Group type: COMPARATOR
Intervention: Femoral Nerve Block (FNB)
Number of subjects: 100
Study 24144880 — intervention group
Group type: EXPERIMENTAL
Intervention: 2000 lux light exposure
Number of subjects: 45
Study 24144880 — intervention group
Group type: EXPERIMENTAL
Intervention: 8000 lux light exposure
Number of subjects: 45
Study 24144880 — intervention group
Group type: COMPARATOR
Intervention: Older adults baseline phase
Number of subjects: 45
Study 22578834 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose CTCA using SAFIRE (protocol B)
Number of subjects: 78
Study 22578834 — intervention group
Group type: COMPARATOR
Intervention: Standard dose CTCA using FBP (protocol A)
Number of subjects: 78
Study 19325451 — intervention group
Group type: EXPERIMENTAL
Intervention: PHiD-CV
Number of subjects: 806
Study 19325451 — intervention group
Group type: COMPARATOR
Intervention: 7vCRM
Number of subjects: 806
Study 17170385 — intervention group
Group type: EXPERIMENTAL
Intervention: AVE5883 (4.8 mg single inhaled dose)
Number of subjects: 32
Study 17170385 — intervention group
Group type: EXPERIMENTAL
Intervention: AVE5883 (4.8 mg three times per day for 9 days)
Number of subjects: 32
Study 17170385 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 16729384 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensorimotor Training followed by High-Intensity Strength Training (SMT-HST)
Number of subjects: 18
Study 16729384 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Strength Training followed by Sensorimotor Training (HST-SMT)
Number of subjects: 18
Study 15067647 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy group fitted with a computer-controlled cooling device for 4 days
Number of subjects: 0
Study 15067647 — intervention group
Group type: COMPARATOR
Intervention: Control group (no cryotherapy)
Number of subjects: 0
Study 15067647 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy group
Number of subjects: 0
Study 10800819 — intervention group
Group type: EXPERIMENTAL
Intervention: On-pump CABG with CPB and cardioplegic arrest
Number of subjects: 60
Study 10800819 — intervention group
Group type: COMPARATOR
Intervention: Off-pump CABG on the beating heart
Number of subjects: 60
Study 8969391 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol-alfentanil anesthesia
Number of subjects: 30
Study 8969391 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane anesthesia
Number of subjects: 30
Study 8969391 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous anesthesia
Number of subjects: 30
Study 8969391 — intervention group
Group type: COMPARATOR
Intervention: Inhalation anesthesia
Number of subjects: 30
Study 1595776 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin plus 10 mg glyburide before breakfast
Number of subjects: 21
Study 1595776 — intervention group
Group type: COMPARATOR
Intervention: Insulin-only group
Number of subjects: 21
Study 3967459 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (240 mg/day after 3 weeks)
Number of subjects: 10
Study 3967459 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol (240 mg/day after 3 weeks)
Number of subjects: 10
Study 3967459 — intervention group
Group type: COMPARATOR
Intervention: Placebo (1 week prior to intervention)
Number of subjects: 10
Study 31025364 — intervention group
Group type: EXPERIMENTAL
Intervention: GuttaFlow Bioseal (GB)
Number of subjects: 36
Study 31025364 — intervention group
Group type: EXPERIMENTAL
Intervention: BioRoot RCS (BR)
Number of subjects: 36
Study 31025364 — intervention group
Group type: COMPARATOR
Intervention: Syringe irrigation (control)
Number of subjects: 36
Study 31025364 — intervention group
Group type: EXPERIMENTAL
Intervention: Tornado Brush
Number of subjects: 36
Study 31025364 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonically activated irrigation
Number of subjects: 36
Study 28195139 — intervention group
Group type: EXPERIMENTAL
Intervention: MDMA-HCl (100 mg p.o.)
Number of subjects: 25
Study 28195139 — intervention group
Group type: COMPARATOR
Intervention: Placebo (ascorbic acid)
Number of subjects: 25
Study 25623603 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored intervention package including core and flexible components with embedded behaviour change techniques.
Number of subjects: 0
Study 25623603 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly detailed in the abstract).
Number of subjects: 0
Study 23478476 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training at 60% 1RM (month 2)
Number of subjects: 64
Study 23478476 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training at 70% 1RM (month 3)
Number of subjects: 64
Study 23478476 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training at 80% 1RM (month 4)
Number of subjects: 64
Study 23478476 — intervention group
Group type: EXPERIMENTAL
Intervention: Postexercise hypotension analyses
Number of subjects: 64
Study 23478476 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 64
Study 21849603 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher protein (HP; 2.9 and 4.4 g protein/100 kcal)
Number of subjects: 1138
Study 21849603 — intervention group
Group type: COMPARATOR
Intervention: Lower protein (LP; 1.77 and 2.2 g protein/100 kcal)
Number of subjects: 1138
Study 21849603 — intervention group
Group type: COMPARATOR
Intervention: Breastfed group
Number of subjects: 1138
Study 20169858 — intervention group
Group type: EXPERIMENTAL
Intervention: Levocetirizine dihydrochloride orally disintegrating tablets with Indion‐204 as taste-masking agent
Number of subjects: 0
Study 20169858 — intervention group
Group type: EXPERIMENTAL
Intervention: Levocetirizine dihydrochloride orally disintegrating tablets with Tulsion‐335 as taste-masking agent
Number of subjects: 0
Study 20169858 — intervention group
Group type: EXPERIMENTAL
Intervention: Levocetirizine dihydrochloride orally disintegrating tablets with crospovidone as superdisintegrant
Number of subjects: 0
Study 20169858 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimum formulation (F‐1) of levocetirizine dihydrochloride orally disintegrating tablets
Number of subjects: 0
Study 20169858 — intervention group
Group type: COMPARATOR
Intervention: Levocetirizine dihydrochloride orally disintegrating tablets
Number of subjects: 0
Study 17944177 — intervention group
Group type: EXPERIMENTAL
Intervention: Tretinoin gel microsphere 0.04%
Number of subjects: 178
Study 17944177 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 178
Study 15554763 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranylcypromine
Number of subjects: 77
Study 15554763 — intervention group
Group type: COMPARATOR
Intervention: Phenelzine
Number of subjects: 77
Study 15554763 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 77
Study 14622808 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized exercise therapy with functional electrical muscle stimulation
Number of subjects: 80
Study 14622808 — intervention group
Group type: COMPARATOR
Intervention: Standardized exercise therapy with placebo electrical stimulation
Number of subjects: 80
Study 9040296 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 1436
Study 9040296 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (tinzaparin sodium)
Number of subjects: 1436
Study 7701032 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactate infusion
Number of subjects: 9
Study 7701032 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 9
Study 3630934 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 9
Study 3630934 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 31599840 — intervention group
Group type: EXPERIMENTAL
Intervention: Bremelanotide 1.75 mg administered subcutaneously as needed
Number of subjects: 1267
Study 31599840 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1267
Study 28562168 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus (TAC) monotherapy at an initial dose of 0.05-0.1 mg/kg/day
Number of subjects: 58
Study 28562168 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide (CTX) combined with corticosteroids (prednisone 1 mg/kg/d) at a dose of 0.5-0.75 g/m2 once every month initially for 6 months
Number of subjects: 58
Study 28562168 — intervention group
Group type: EXPERIMENTAL
Intervention: Both TAC and CTX groups
Number of subjects: 58
Study 28562168 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus (TAC) monotherapy
Number of subjects: 58
Study 25952743 — intervention group
Group type: EXPERIMENTAL
Intervention: Percentage + risk label format
Number of subjects: 368
Study 25952743 — intervention group
Group type: COMPARATOR
Intervention: Other 3 formats (frequency, percentage, frequency + risk label)
Number of subjects: 368
Study 22994550 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo alcohol
Number of subjects: 77
Study 22994550 — intervention group
Group type: COMPARATOR
Intervention: Soft drink
Number of subjects: 77
Study 21543239 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose zonisamide (3-4 mg/kg/day)
Number of subjects: 125
Study 21543239 — intervention group
Group type: COMPARATOR
Intervention: High-dose zonisamide (6-8 mg/kg/day)
Number of subjects: 125
Study 19327416 — intervention group
Group type: EXPERIMENTAL
Intervention: Periprocedural bleeding complications (none, mild, moderate, severe)
Number of subjects: 6995
Study 19327416 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood transfusion
Number of subjects: 6995
Study 16969725 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-pole Stablemapr mapping catheter (G1)
Number of subjects: 30
Study 16969725 — intervention group
Group type: COMPARATOR
Intervention: Conventional mapping (G2)
Number of subjects: 30
Study 14976886 — intervention group
Group type: EXPERIMENTAL
Intervention: Shenfu injection (SFI) 1 ml/kg intravenous infusion 30 min before anesthesia
Number of subjects: 120
Study 14976886 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 120
Study 12588572 — intervention group
Group type: EXPERIMENTAL
Intervention: Home intervention including a diagnostic home visit, assessing the home for environmental hazards, advice about possible changes, offer of facilities for necessary home modifications, and training in the use of technical and mobility aids.
Number of subjects: 360
Study 12588572 — intervention group
Group type: COMPARATOR
Intervention: Usual care at home (control group).
Number of subjects: 360
Study 12588572 — intervention group
Group type: EXPERIMENTAL
Intervention: Home intervention in a subgroup of participants with two or more falls in the year before recruitment.
Number of subjects: 360
Study 10762749 — intervention group
Group type: EXPERIMENTAL
Intervention: Pion radiotherapy
Number of subjects: 215
Study 10762749 — intervention group
Group type: COMPARATOR
Intervention: Photon radiotherapy
Number of subjects: 215
Study 10762749 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormonal therapy
Number of subjects: 215
Study 8985767 — intervention group
Group type: EXPERIMENTAL
Intervention: Plastic blunt cannula (PBC)
Number of subjects: 0
Study 8985767 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-way valve (2-way)
Number of subjects: 0
Study 8985767 — intervention group
Group type: EXPERIMENTAL
Intervention: Metal blunt cannula (MBC)
Number of subjects: 0
Study 8985767 — intervention group
Group type: COMPARATOR
Intervention: Traditional needled devices (Control)
Number of subjects: 0
Study 1638661 — intervention group
Group type: EXPERIMENTAL
Intervention: Moving the place for vaccination close to the consulting room
Number of subjects: 0
Study 1638661 — intervention group
Group type: EXPERIMENTAL
Intervention: Doctor writing a prescription recommending vaccination
Number of subjects: 0
Study 1638661 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 2982538 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenaline infusion with intra-arterial propranolol
Number of subjects: 6
Study 2982538 — intervention group
Group type: EXPERIMENTAL
Intervention: Noradrenaline infusion with intra-arterial propranolol
Number of subjects: 6
Study 2982538 — intervention group
Group type: COMPARATOR
Intervention: Doxazosin infusion
Number of subjects: 6
Study 2982538 — intervention group
Group type: COMPARATOR
Intervention: Yohimbine infusion
Number of subjects: 6
Study 30989763 — intervention group
Group type: EXPERIMENTAL
Intervention: Shelter services for women
Number of subjects: 183
Study 30989763 — intervention group
Group type: COMPARATOR
Intervention: Shelter services for men
Number of subjects: 183
Study 30989763 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in social quality factors over time
Number of subjects: 183
Study 29028364 — intervention group
Group type: EXPERIMENTAL
Intervention: Empowerment program
Number of subjects: 60
Study 29028364 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 60
Study 27511182 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta‐1b (early treatment)
Number of subjects: 468
Study 27511182 — intervention group
Group type: COMPARATOR
Intervention: Placebo (delayed treatment)
Number of subjects: 468
Study 27511182 — intervention group
Group type: COMPARATOR
Intervention: MRI metrics
Number of subjects: 468
Study 24361086 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous diclofenac HPbCD administered in quadriceps
Number of subjects: 12
Study 24361086 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous diclofenac HPbCD administered in gluteus
Number of subjects: 12
Study 24361086 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous diclofenac HPbCD administered in abdomen
Number of subjects: 12
Study 21584681 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate supplementation (maltodextrin solution)
Number of subjects: 24
Study 20369059 — intervention group
Group type: EXPERIMENTAL
Intervention: MF59-adjuvanted influenza vaccine (Sub/MF59)
Number of subjects: 199
Study 20369059 — intervention group
Group type: COMPARATOR
Intervention: Virosomal vaccine (SVV)
Number of subjects: 199
Study 20369059 — intervention group
Group type: COMPARATOR
Intervention: Split vaccine
Number of subjects: 199
Study 18823656 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan 16 mg once a day, increased to 32 mg after 1 month
Number of subjects: 3326
Study 18823656 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3326
Study 16009798 — intervention group
Group type: EXPERIMENTAL
Intervention: Effective nasal continuous positive airway pressure (nCPAP) for 12 weeks
Number of subjects: 27